ReviewFrontiers in endocrinology2026
From incidentaloma to actionable insight: a clinical-molecular-imaging framework for risk-stratified management of testicular microlithiasis.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Testicular microlithiasis (TM) is common in infertile men, but its management is controversial due to an unclear link to testicular germ cell tumor (TGCT) risk. This scoping review synthesizes evidence to clarify the basis for personalized management of TM, focusing on infertile men. Methods: Following PRISMA-ScR guidelines, we systematically searched PubMed, Embase, and Web of Science (2015-2025) for studies on TM pathogenesis, imaging, molecular mechanisms, management, and TGCT association. Data were charted and narratively synthesized. Results: TM and TGCT share molecular pathways (e.g., KIT/KITLG, BMP7) within testicular dysgenesis syndrome. Isolated TM carries minimal risk, while coexisting with factors like cryptorchidism, infertility, or family history significantly elevates TGCT risk. Advanced imaging and liquid biopsy markers (e.g., miR-371a-3p) may refine risk assessment. Intermediate-risk patients (TM plus one established risk factor) may be considered for periodic ultrasound within shared decision-making; routine biomarker testing is not supported and should be individualized to selected high-risk contexts. Conclusion: The available evidence remains heterogeneous, and routine imaging surveillance for isolated testicular microlithiasis is not supported. We propose an evidence-informed, hypothesis-generating risk-stratification framework to support shared decision-making and highlight priorities for prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.